Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease

American Journal of Medicine

Volumn 127, Issue 1, 2014, Pages

  Bangalore, Sripal ^a   Fayyad, Rana ^b   Laskey, Rachel ^b   Demicco, David A ^b   Deedwania, Prakash ^c   Kostis, John B ^d   Messerli, Franz H ^e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e College of Physicians and Surgeons ^*  (United States)

Author keywords

Outcome; Predictors; Prevalence; Resistant hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RESISTANT HYPERTENSION;

EID: 84891633653     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2013.07.038     Document Type: Article

References (20)

1. B.M. Egan, Y. Zhao, and R.N. Axon US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008 JAMA 303 2010 2043 2050
2. F.H. Messerli, and S. Bangalore Treatment-resistant hypertension: another Cinderella story Eur Heart J 34 2013 1175 1177
3. D.A. Calhoun, D. Jones, and S. Textor et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Circulation 117 2008 e510 e526
4. M.R. Irvin, D. Shimbo, and D.M. Mann et al. Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension J Clin Hypertens (Greenwich, Conn) 14 2012 694 700
5. B.M. Egan, Y. Zhao, and R.N. Axon et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008 Circulation 124 2011 1046 1058
6. S.L. Daugherty, J.D. Powers, and D.J. Magid et al. Incidence and prognosis of resistant hypertension in hypertensive patients Circulation 125 2012 1635 1642
7. S.D. Persell Prevalence of resistant hypertension in the United States, 2003-2008 Hypertension 57 2011 1076 1080
8. D.D. Waters, J.R. Guyton, and D.M. Herrington et al. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 93 2004 154 158
9. J.C. LaRosa, S.M. Grundy, and D.D. Waters et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
10. D.J. Kumbhani, P.G. Steg, and C.P. Cannon et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis Eur Heart J 34 2012 1204 1214
11. J.L. Anderson, C.D. Adams, and E.M. Antman et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J Am Coll Cardiol 50 2007 e1 e157
12. S. Bangalore, F.H. Messerli, and C.C. Wun et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial Eur Heart J 31 2010 2897 2908
13. S. Bangalore, J. Qin, and S. Sloan et al. What is the optimal blood pressure in patients after acute coronary syndromes?: relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial Circulation 122 2010 2142 2151
14. W.C. Cushman, G.W. Evans, and R.P. Byington et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 2010 1575 1585
15. J.G. Douglas, G.L. Bakris, and M. Epstein et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks Arch Intern Med 163 2003 525 541
16. W.C. Cushman, C.E. Ford, and J.A. Cutler et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) J Clin Hypertens (Greenwich) 4 2002 393 404
17. C. Cuspidi, G. Macca, and L. Sampieri et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension J Hypertens 19 2001 2063 2070
18. G. Grassi, G. Seravalle, G. Brambilla, and G. Mancia The sympathetic nervous system and new nonpharmacologic approaches to treating hypertension: a focus on renal denervation Can J Cardiol 28 2012 311 317
19. J.D. Bisognano, G. Bakris, and M.K. Nadim et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial J Am Coll Cardiol 58 2011 765 773
20. M.D. Esler, H. Krum, and P.A. Sobotka et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial Lancet 376 2010 1903 1909